Details of the Drug Reposition

General Information of This Drug (ID: DMLEHQ3)

• Drug Name: Anti-CEA CAR-T therapy (DMLEHQ3)

Information on Drug Reposition of This Drug

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Metastatic liver cancer	DISWGRQI	2C12	Phase 1	[1]
Liver metastasis	DISR7SOX	2D80	Phase 1	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)